Statistical Consulting

Experts in statistical consulting deliver strategic insight, advanced methods, and tech-enabled support for confident decision-making for clinical development.

At MMS, our Statistical Consulting Services are designed to go beyond analysis. We bring partnership, foresight, and innovation to every stage of your clinical development journey. Our consultants provide the clarity, technical expertise, and technology-enabled solutions needed to make confident, data-driven decisions that move your program forward.

Flexible, Integrated Project Support

Our statistical consulting experts are more than technical leads, they are embedded partners. MMS collaborate closely with sponsors, adapting to your unique needs, timelines, and teams. With deep industry knowledge and end-to-end development experience, our statisticians bring flexibility, responsiveness, and strategic foresight to every engagement.

How MMS Delivers Value:

  • Trusted partnership from experienced statisticians
  • Seamless integration with cross-functional teams including programming, data management, data science, medical writing, and clinical operations.
  • Clear, contextualized communication of statistical rationale
  • Flexible support across the development lifecycle
Study Design Support and Evaluation

We deliver evidence-based, pragmatic guidance to help sponsors evaluate risk, explore options, and make the right choices early. Our team of MMS experts applies a variety of simulation tools and statistical techniques to assess your study design, development plan, and strategic opportunities allowing your clinical development teams to maximize probability of success and adjust when needed.

MMS Supports Clinical Teams With:

  • Study design and development plan evaluation
  • Estimand strategies and protocol input
  • Use of our technology enabled solutions KerusCloud® to model outcomes and optimize trial design
  • Critical review and amendment of existing designs
Custom Strategies for your Development Pipeline

Our statisticians are equipped to implement complex and novel methodologies tailored to the needs of your asset. Whether using Bayesian frameworks, designing synthetic control arms, or advising on estimands selection, we ensure the right technical solution is applied with clarity and rigor.

Tailored MMS Solutions Include:

  • Complex analysis using Bayesian and other advanced methods
  • Application of appropriate estimands strategies
  • Implementation of external or synthetic control arms
  • Quantitative support for investment decisions
Regulatory Engagement

MMS statisticians act as authoritative voices and trusted advocates for your program. From regulatory meetings to vendor oversight and independent statistical roles, we ensure that your statistical interests are clearly represented, protected, and aligned with your development goals.

How MMS Can Support:

  • Regulatory submission and meeting preparation
  • Oversight of external data or statistical vendors
  • Independent statistician roles for monitoring committees
  • High-quality deliverables aligned with regulatory expectations

Suggested For You

news

June 19th, 2025

MMS Wins in the 2025 Fierce CRO Awards for Excellence in Client Service and Partnership and Dr. Uma Sharma Named CRO Champion 

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

regulatory intelligence

June 16th, 2025

Key MedDRA Coding Gaps Highlighted at the ISCTM 2025 Scientific Meeting

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution